PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Recommendation of “Moderate Buy” from Analysts

PolyPid Ltd. (NASDAQ:PYPD) has received an average recommendation of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $12.25.

PYPD has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $13.00 price objective on shares of PolyPid in a research note on Wednesday, February 11th. Citigroup restated a “market outperform” rating on shares of PolyPid in a research report on Monday, December 1st. Wall Street Zen raised shares of PolyPid from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of PolyPid in a research report on Monday, December 29th.

Institutional Investors Weigh In On PolyPid

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its stake in shares of PolyPid by 56.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after purchasing an additional 3,500 shares during the last quarter. HighTower Advisors LLC acquired a new position in shares of PolyPid during the 4th quarter worth $44,000. Jane Street Group LLC bought a new stake in shares of PolyPid during the 4th quarter worth $66,000. XTX Topco Ltd lifted its position in shares of PolyPid by 50.0% during the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock worth $142,000 after buying an additional 10,888 shares during the last quarter. Finally, Lumbard & Kellner LLC acquired a new stake in PolyPid in the second quarter valued at about $135,000. 26.47% of the stock is currently owned by institutional investors.

PolyPid Stock Performance

NASDAQ:PYPD opened at $4.39 on Thursday. The stock has a fifty day moving average price of $4.44 and a 200-day moving average price of $3.95. The company has a market cap of $83.76 million, a price-to-earnings ratio of -1.94 and a beta of 1.49. PolyPid has a fifty-two week low of $2.30 and a fifty-two week high of $5.12.

PolyPid (NASDAQ:PYPD) last issued its quarterly earnings results on Wednesday, February 11th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07). Research analysts predict that PolyPid will post -1.79 EPS for the current fiscal year.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.